Winrevair Approved for Pulmonary Arterial Hypertension
Winrevair is a first-in-class recombinant activin receptor type IIA-Fc fusion protein designed to bind to activin A and other TGF-β superfamily ligands.
Winrevair is a first-in-class recombinant activin receptor type IIA-Fc fusion protein designed to bind to activin A and other TGF-β superfamily ligands.
In this episode of Annals On Call, Dr. Centor discusses the current increase in cases of dengue with Drs. Davidson Hamer and Ralph Huits.
Strategies for intervention design focused on opportunities for both patients and providers by way of medication labeling, specific prescription instructions, prescribing prompts, and educational services.
The expanded approval was based on data from 4 randomized, active-controlled, parallel-group clinical studies, which compared the efficacy and safety of Clinolipid to soybean oil-based…
Background The ageing process is a multifaceted phenomenon marked by the gradual deterioration of cellular and organismal functions, accompanied by an elevated susceptibility to diseases.…
Stephen Bradley and colleagues argue that plans to involve community pharmacies in diagnosing cancer are unlikely to transform cancer detection in primary care Cancer is…
Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according…
Addressing the long-term effects of RSV in older adults is crucial for public health and patient care.
Ramping up efforts against anticompetitive practices in business.
This randomized clinical trial evaluates the use of acupuncture in the treatment of xerostomia in patients with head and neck cancer who received radiotherapy.
Globally, hypertension is estimated to affect 1.28 billion adults aged 30-79 years, the majority of whom have uncontrolled hypertension.1 In the United States, almost half…